The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 336:1822-1824 June 19, 1997 Number 25
NextNext

Hematopoietic Growth Factors — Not Whether, but When and Where

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Many studies have appraised the value of treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte–macrophage colony-stimulating factor (GM-CSF) in ameliorating chemotherapy-induced neutropenia. The principal aim of this treatment is to reduce the risk of infection, thereby minimizing the need for hospitalization and parenteral antibiotics. In several clinical trials, the administration of G-CSF or GM-CSF after chemotherapy did not prevent neutropenia but did shorten its duration. In some of the studies, patients treated with colony-stimulating factor had fewer febrile episodes, fewer hospitalizations, and shorter hospital stays than patients not receiving this treatment, but it had no influence on the frequency of . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.